Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

These Catalent sites are already involved in Novo Nordisk manufacturing contracts, which are largely tied to ramping up supply of the firm’s obesity drug Wegovy. Novo Nordisk expects that ...

Novo Nordisk has become Europe’s most valuable company due to soaring demand for its weight-loss-aiding drugs Wegovy, Semaglutide, and Ozempic. But as the effective backbone of the Danish ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up.